Overview
Dr. Granstein's research interests center on the regulation of immunity within the skin and the relationship of the skin's immune system to the development of skin cancers. He also has a special research interest in the regulation of the immune system by stress and the nervous system. He was the first to demonstrate that certain immune cells within the skin are capable of initiating an immune response against a malignant tumor and that immune cells within the epidermis (the upper layer of the skin) have an anatomic relationship with nerves and can be regulated by proteins produced by those nerves. His clinical interests include autoimmune disorders of the skin, skin cancer, and psoriasis.
Highlights
- 1Journal of immunology (Baltimore, Md. : 1950) · 2022
- 2Immunology · 2025
- 3Photodermatology, photoimmunology & photomedicine · 2024
Publications
Funding
Active
1 grant- PILF-OC-22-001088Studies on Immune Effects of CGRP Signaling Through Endothelial CellsLEO Foundation · 2023–2026
Completed grants (8)
- PISRA 223611-01CGRP, Stress and ImmunityHoward and Abby Milstein Foundation · 2022–2024Contract
- PISRA 191409-03Studies on Inhibition of Ultraviolet Radiation Effects by Basis, additional dose ranging experimentsElysium Health · 2018–2021Contract
- PILF 180675-03Regulation of immunity by calcitonin gene-related peptide through effects on endothelial cells.LEO Foundation · 2017–2021
- PIWI238750-02Regulation of Langerhans Cell Antigen-Presenting Function by Interleukin-6Pfizer Inc. · 2018–2020
- PIElysium SRARDG_Studies on Inhibition of UVR Effects by BasisElysium Health · 2017–2018Contract
- PIR21AR064907-02 EWNeurotransmitter Regulation of Immunity Through Effects on Endothelial CellsNational Inst of Arthritis & Musculoskeletal & Skin Diseases · 2014–2017
- PIR01AR042429-15Langerhans Cells and Nerves: Bidirectional SignalingNIAMS · 1992–2012 · via NIH RePORTER
- PIR21AI059226-02Vaccine Development: Purinergic Agonists as AdjuvantsNIAID · 2004–2007 · via NIH RePORTER
Honors & distinctions
- Member · American Society for Clinical Investigation · 1994
Clinical research
Active
1 study- PIAnalyses of JAK-STAT Signaling in Central Centrifugal Cicatricial Alopecia: Identifying Potential Therapeutic TargetsWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2021)
Completed & closed trials (4)
- PINCT04629950A Pilot Study of Rimegepant in Moderate Plaque-type PsoriasisPHASE2 · Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2026)Psoriasis
- PITralokinumab Real World Clinical Use: An observational cohort study of atopic dermatitis patients prescribed tralokinumabLEO Pharma Inc. · IRB STUDY CLOSURE (as of 2025)
- PINCT04501679A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo NodularisPHASE3 · Galderma S.A. · IRB STUDY CLOSURE (as of 2022)Prurigo Nodularis
- PIDoes rash and/or complement component deposition in dermal blood vessels in COVID-19 patients portend severe disease?Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2021)
News mentions
- Commercial Astronauts Shed Light on Flights’ Health Impacts and Create Spaceflight AtlasJune 11, 2024
Molecular and physiological changes in space travelers reveal new targets for aerospace medicine and can guide new missions, according to the results of a massive international research endeavor by investigators at Weill Cornell Medicine, SpaceX, and other organizations.
Mentoring
- YJYee Jung KimMD mentee · Class of 2022
- JZJoshua ZeitlinMD mentee · Class of 2021
External relationships
Ownership
BelleTorus Corporation · Elysium Health · Novaestiq Corporation
Advisory/Scientific Board Member
Amorepacific Corporation · Elysium Health · Gore Range Capital LLC · National Rosacea Society
Other Interest
National Rosacea Society
Other
BelleTorus Corporation